Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niklas Mattsson

Showing results (191-200 of 395) with videos related to

Pageof 40
Sort By:
Alzheimer'S Research & Therapy|November 19, 2014
β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavageErik Portelius, Robert A Dean, Ulf Andreasson, et al.
EMBO Molecular Medicine|November 12, 2019
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's diseaseSebastian Palmqvist, Philip S Insel, Erik Stomrud, et al.
Psychoneuroendocrinology|March 12, 2013
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's diseasePer Johansson, Daniel Åberg, Jan-Ove Johansson, et al.
Brain : a Journal of Neurology|October 17, 2020
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's diseaseNiklas Mattsson-Carlgren, Shorena Janelidze, Sebastian Palmqvist, et al.
Biochemical and Biophysical Research Communications|August 17, 2011
The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosisCamilla Hesse, Inger Johansson, Niklas Mattsson, et al.
Brain : a Journal of Neurology|July 14, 2021
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's diseaseJoana B Pereira, Shorena Janelidze, Ruben Smith, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 16, 2014
The transitional association between β-amyloid pathology and regional brain atrophyPhilip S Insel, Niklas Mattsson, Michael C Donohue, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersAmanda Annettesdotter, Nicola Spotorno, Anika Wuestefeld, et al.
Neurology and Therapy|July 20, 2025
Clinical Performance of the Elecsys CSF pTau<sub>181</sub>/Aβ<sub>42</sub> Ratio for Concordance with Tau-PET in Two Independent CohortsRuben Smith, Leslie Shaw, Sebastian Palmqvist, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumAmanda Annettesdotter, Nicola Spotorno, Anika Wuestefeld, et al.
Pageof 40

Showing results (191-200 of 395) with videos related to

Sort By:
Pageof 40
Alzheimer'S Research & Therapy|November 19, 2014
β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavageErik Portelius, Robert A Dean, Ulf Andreasson, et al.
EMBO Molecular Medicine|November 12, 2019
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's diseaseSebastian Palmqvist, Philip S Insel, Erik Stomrud, et al.
Psychoneuroendocrinology|March 12, 2013
Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's diseasePer Johansson, Daniel Åberg, Jan-Ove Johansson, et al.
Brain : a Journal of Neurology|October 17, 2020
Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's diseaseNiklas Mattsson-Carlgren, Shorena Janelidze, Sebastian Palmqvist, et al.
Biochemical and Biophysical Research Communications|August 17, 2011
The N-terminal domain of α-dystroglycan, released as a 38 kDa protein, is increased in cerebrospinal fluid in patients with Lyme neuroborreliosisCamilla Hesse, Inger Johansson, Niklas Mattsson, et al.
Brain : a Journal of Neurology|July 14, 2021
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's diseaseJoana B Pereira, Shorena Janelidze, Ruben Smith, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 16, 2014
The transitional association between β-amyloid pathology and regional brain atrophyPhilip S Insel, Niklas Mattsson, Michael C Donohue, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
BiomarkersAmanda Annettesdotter, Nicola Spotorno, Anika Wuestefeld, et al.
Neurology and Therapy|July 20, 2025
Clinical Performance of the Elecsys CSF pTau<sub>181</sub>/Aβ<sub>42</sub> Ratio for Concordance with Tau-PET in Two Independent CohortsRuben Smith, Leslie Shaw, Sebastian Palmqvist, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Alzheimer's Imaging ConsortiumAmanda Annettesdotter, Nicola Spotorno, Anika Wuestefeld, et al.
Pageof 40